Solid drug nanoparticles
Fundamentals of Pharmaceutical Nanoscience, Page: 63-88
2024
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Solid drug nanoparticles (SDNs) are formulations in which the drug presents as a sub-micron particle stabilised by surfactants, polymers or sugars. These formulations are prepared using scalable industrial processes and contain high levels of drug compared to excipient. They may be prepared by milling or other size reduction techniques or by self-assembly or nanoprecipitation methods. SDNs may be used to significantly improve oral bioavailability, or deliver hydrophobic drugs as a suspension via the intravenous or subcutaneous routes for a long-acting outcome. SDNs may also be used via the pulmonary route or for topical application to the skin or ocular surface tissues. Many approved formulations exist for clinical use, demonstrating their versatility.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know